80 related articles for article (PubMed ID: 8866760)
1. Therapeutic receptor-blocking concentrations of neuroleptics.
Seeman P
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():5-13. PubMed ID: 8866760
[TBL] [Abstract][Full Text] [Related]
2. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors.
Seeman P; Corbett R; Van Tol HH
Neuropsychopharmacology; 1997 Feb; 16(2):93-110; discussion 111-35. PubMed ID: 9015795
[TBL] [Abstract][Full Text] [Related]
3. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand.
Seeman P; Van Tol HH
Eur J Pharmacol; 1995 Oct; 291(2):59-66. PubMed ID: 8566176
[TBL] [Abstract][Full Text] [Related]
4. Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism.
Seeman P; Corbett R; Nam D; Van Tol HH
Jpn J Pharmacol; 1996 Jul; 71(3):187-204. PubMed ID: 8854201
[TBL] [Abstract][Full Text] [Related]
5. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
6. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
Seeman P; Guan HC; Van Tol HH; Niznik HB
Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
[TBL] [Abstract][Full Text] [Related]
7. Dopamine receptor pharmacology.
Seeman P; Van Tol HH
Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
[TBL] [Abstract][Full Text] [Related]
8. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.
Kapur S; Seeman P
J Psychiatry Neurosci; 2000 Mar; 25(2):161-6. PubMed ID: 10740989
[TBL] [Abstract][Full Text] [Related]
10. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.
Seeman P
Neuropsychopharmacology; 1992 Dec; 7(4):261-84. PubMed ID: 1362057
[TBL] [Abstract][Full Text] [Related]
12. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
Van Tol HH; Bunzow JR; Guan HC; Sunahara RK; Seeman P; Niznik HB; Civelli O
Nature; 1991 Apr; 350(6319):610-4. PubMed ID: 1840645
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
14. Dopamine receptors and the dopamine hypothesis of schizophrenia.
Seeman P
Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
[TBL] [Abstract][Full Text] [Related]
15. Clozapine occupies high levels of dopamine D2 receptors.
Seeman P; Kapur S
Life Sci; 1997; 60(12):PL 207-16. PubMed ID: 9061054
[TBL] [Abstract][Full Text] [Related]
16. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
Patel S; Freedman S; Chapman KL; Emms F; Fletcher AE; Knowles M; Marwood R; Mcallister G; Myers J; Curtis N; Kulagowski JJ; Leeson PD; Ridgill M; Graham M; Matheson S; Rathbone D; Watt AP; Bristow LJ; Rupniak NM; Baskin E; Lynch JJ; Ragan CI
J Pharmacol Exp Ther; 1997 Nov; 283(2):636-47. PubMed ID: 9353380
[TBL] [Abstract][Full Text] [Related]
17. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex.
Kusumi I; Ishikane T; Matsubara S; Koyama T
J Neural Transm Gen Sect; 1995; 101(1-3):231-5. PubMed ID: 8695053
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.
Lyles-Eggleston M; Altundas R; Xia J; Sikazwe DM; Fan P; Yang Q; Li S; Zhang W; Zhu X; Schmidt AW; Vanase-Frawley M; Shrihkande A; Villalobos A; Borne RF; Ablordeppey SY
J Med Chem; 2004 Jan; 47(3):497-508. PubMed ID: 14736232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
